Ulcerative Colitis CD19+ B Cells

Ulcerative Colitis CD19+ B Cells for Mucosal Immunology Research

Ulcerative Colitis CD19+ B Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with ulcerative colitis. These CD19+ B cells reflect disease-associated humoral alterations and support studies of mucosal immunity, antibody responses, and B cell activation in inflammatory bowel disease.

B Cells in Ulcerative Colitis

Ulcerative colitis is an immune-mediated inflammatory bowel disease in which a dysregulated mucosal immune response to intestinal microbiota drives continuous colonic inflammation in genetically susceptible individuals. It is generally classed as immune-mediated rather than classically autoimmune, since no single pathogenic autoantigen defines it — a distinction worth keeping in view when designing B cell work:

• pANCA positivity in a majority of UC donors — a useful serological marker that distinguishes UC from Crohn’s disease, though not itself pathogenic
• Anti-microbiota antibody responses, reflecting loss of tolerance to commensal flora rather than to self
• IgG subclass skewing — UC characteristically shows an IgG1-dominant mucosal response, in contrast to the IgG2 skew of Crohn’s disease
• Plasma cell expansion in the lamina propria and altered circulating plasmablast frequency during active disease
• Reduced regulatory B cell function
• Lymphocyte trafficking — vedolizumab targets α4β7 integrin, so anti-integrin-treated donors show altered circulating populations

Donor Stratification Available

• Disease activity — Mayo score, UCEIS, or partial Mayo where recorded; active flare vs remission
• Disease extent — proctitis, left-sided colitis, or pancolitis
• pANCA and ASCA serology where tested
• Inflammatory markers — CRP and faecal calprotectin where available
• Treatment status — 5-ASA, thiopurine, anti-TNF, anti-integrin, or JAK inhibitor
• Matched healthy controls, and Crohn’s disease donors for differential IBD comparison

Product Features

• Research Use Only (RUO), CD19+ enriched B cells
• Isolated from clinically diagnosed ulcerative colitis donors
• High viability and enrichment
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Flow cytometry purity and viability data per lot
• Ethically sourced with IRB approval and HIPAA compliance

De-identified Donor Data

• Confirmed diagnosis of ulcerative colitis
• Demographics: age, sex assigned at birth, race/ethnicity
• Self-reported clinical history and medication use

Applications

• B cell phenotyping and function in ulcerative colitis
• Mucosal humoral immunity and anti-microbiota antibody studies
• pANCA and IBD serology research
• BCR repertoire sequencing and IgG subclass analysis
• Differential IBD studies — UC vs Crohn’s disease
• Biologic mechanism-of-action research
• Disease mechanism studies and biomarker identification
• Preclinical immunotherapy development

Other Ulcerative Colitis Specimen Types

Matched material is available as UC CD56+ NK cells and UC leukopak. For the broader IBD category see inflammatory bowel disease CD19+ B cells and IBD leukopak.

Compliance and Quality Assurance

• IRB-approved collection and 21 CFR Part 11-compliant e-consent
• Standardized processing and quality protocols
• HIPAA-compliant data handling

Ordering & Customization

Ulcerative Colitis CD19+ B Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD19+ B cells collection.